'Pharmacy should base specials decisions on more than price' - An article Published by C&D

Please click here to view the article published 10th November 2011.

Comments

Post a Comment

Popular posts from this blog

Specials medicines vital for vulnerable patients

During the COVID-19 outbreak, APSM members are taking all appropriate measures to ensure the continuity of supply of specials medicines to community pharmacies, dispensing doctors and hospitals.   Specials manufacturers are a vital part of the pharmaceutical supply chain, responsible for around 50,000 unlicensed medicine prescriptions for vulnerable patients in England each month.  The Association of Pharmaceutical Specials Manufacturers represents around 80% of specials manufacture in England and its members are maintaining safe practices and committing to the ongoing fulfilment of all orders from their pharmacy customers throughout the pandemic. As specials are often prescribed to patients in vulnerable groups including the elderly, paediatrics and those with chronic health conditions, it has never been more important that these patients’ essential medication needs are met in a timely way.  Where possible, our members are continuing to meet thei...
Read more

APSM expands membership to reflect changing role of specials industry

The Association of Pharmaceutical Specials Manufacturers, APSM, has broadened its membership criteria to include importers as well as virtual Specials manufacturing organisations who own the rights to, and act as the first supplier of, a Specials medicine in the UK. Originally founded to represent the interests of holders of a Specials Manufacturing Licence, the APSM has an important role liaising with the DH and key policy makers as well as inputting into decisions around new legislation and Specials guidance. The decision to broaden membership to the wider supply chain reflects the changing shape of the Specials market, particularly over the last 5 years following the introduction of the Specials Tariff alongside a developing regulatory framework and professional guidance around Specials.  Influencing and responding to issues in this changing market has also become a more important role for the APSM. APSM Chair, Sharon Griffiths, said, “The decisions and actions we take n...
Read more

Specials record another year of delivering increased value to the NHS

The Specials Market in primary care was just over £ 80.5 million for the 12 month period Oct 15 - Sep 16.  Although the market continues to decline year-on-year, it is now stabilising following a period of readjustment in the wake of the Specials Tariff in November 2011.  During this time the mean cost per item has reduced from £180 per item before the tariff in Nov 2011, to an average £116 for the same 12 month period to Sep 2016. Whilst this represents value for money to the NHS, at the same time the high standards of quality involved in Specials manufacture have needed to be maintained.  According to the Association of Pharmaceutical Specials Manufacturers, APSM, members report continued investment in infrastructure and quality processes to meet the increasing regulatory demands required by the sector. To reflect the increased complexity of the market, l ast year (2016), the Association of Pharmaceutical Specials Manufacturers, APSM, decided to broaden its mem...
Read more